Most Recent
Drug maker Janssen will drop its long-running patent lawsuit against Alphapharm after the generic drug maker agreed to refrain from making products that allegedly infringe Janssen's patents for its HIV drug Prezista.
A judge has signed off on the lead applicants' bid to expand the current group definition in a class action against Johnson & Johnson unit Ethicon over allegedly defective vaginal mesh products, saying there was "no reason in logic" why the request should be denied.
German medical device company B. Braun Melsungen has dropped its appeal of a ruling invalidating three of its intravenous catheter patents and finding rival Becton Dickinson did not infringe the patents.
After losing its fight for a temporary injunction, Sanofi-Aventis has dropped its patent lawsuit against Alphapharm over the generic drug maker's plans to market a competing insulin injector pen in Australia.
A judge has refused an application by generic drug maker Juno Pharmacueticals to withdraw an admission in a battle with Millennium Pharmaceuticals over its cheap version of breakthrough cancer drug Velcade, denying Juno a potential defence to allegations of patent infringement.
Horse vaccine maker Zoetis has appealed a ruling that denied its request for $450,000 as security for costs in an unfunded class action accusing it of failing to warn about the vaccine's side effects.
The founder and former CEO of Smiles Inclusive has been taken to court by the dental company, which accuses him of serious misconduct over allegedly unlawful payments and transactions.
The Australian Competition and Consumer Commission has brought legal action against Bupa alleging the aged care provider charged thousands of residents for promised extra services it did not provide.
Generic drug maker Sandoz has secured a retroactive licence to manufacture a cheaper version of top-selling antidepressant Lexapro, the drug at the heart of a long-running patent infringement battle with pharmaceutical giant Lundbeck.
A judge has denied Mylan's bid to temporarily block Sun Pharma and Cipla from making generic versions of anti-cholesterol drug Lipidil while it appeals a ruling invalidating several claims of its patents for the drug, citing the "difficulty, complexity and uncertainty" in assessing compensation under an undertaking as to damages in pharmaceutical patent proceedings.